PT - JOURNAL ARTICLE AU - Jiang, Bibo AU - Wang, Li AU - Leslie, Douglas TI - Cross-state variation in opioid use disorder among a privately insured nonelderly population in the United States AID - 10.1101/2020.06.09.20121269 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20121269 4099 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20121269.short 4100 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20121269.full AB - Background Although cross-state variation of the opioid epidemic in the United States are well documented in general, little are known about the epidemic in privately insured individuals.Objectives To describe cross-state variation in Opioid Use Disorder (OUD) among privately insured individuals in the US for the years 2005-2015 and investigate demographic differences of OUD patients between a group of hard-hit states and the rest states.Methods The MarketScan® Commercial Claims and Encounters database was used to calculate prevalence of opioid use disorder for the 50 states in the US, respectively. We analyzed level and change of OUD prevalence in each state from 2005 to 2015 and identified the states which were affected most by the epidemic. One-sided exact fisher test was used to analyze demographic difference of the epidemic in the hard-hit states and the remaining states.Results Cross-state variations of the opioid epidemic among privately insured population were substantial, both in terms of severity and acceleration of the epidemic. Demographic patterns of the epidemic were similar across states. The 18-34 age group was the most affected group with the highest prevalence. The 55-64 group experienced the most rapid increase of OUD prevalence, especially in states that suffered most in the epidemic.Conclusions Results can assist policy makers to design better clinical and policy interventions on the opioid epidemic, especially on privately insured individuals. Drastic increase of OUD prevalence among the 55-64 group might indicate the need to improve prescription drug monitoring programs for chronic pain, especially in states more affected by the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only secondary data from private insurance medical claims database (Marketscan). The database has been stripped of identifiers. The research material obtained from human subjects is in the form of data acquired from IBM Truven Health Analytics, specially designed for research use. The subjects from the database that made available to us can be neither identifiable nor linkable by us.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study used only secondary data from private insurance medical claims database (Marketscan). Although we are not allowed to share the data. The data are publicly available with purchase.